In 10 years, NHGRI hopes to take DNA sequencers from the lab to the clinic, but some companies think 10 years isn't soon enough, says Forbes' Matthew Herper. Illumina's Jay Flatley has already talked about getting regulatory approval "to use his technology for medical purposes," Herper says. And even though regulatory approval — whether of the sequencers themselves or the interpretation of the sequence is unclear — is only the first hurdle.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.

NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.

In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.